Zacks Investment Research upgraded shares of Anthera Pharmaceuticals (NASDAQ:ANTH) from a hold rating to a buy rating in a research note published on Monday. Zacks Investment Research currently has $1.75 price objective on the biopharmaceutical company’s stock.
According to Zacks, “Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products to treat serious illnesses, including cardiovascular and autoimmune diseases. The Company’s clinical-stage programs include one Phase 3 ready program, A-002, and two Phase 2 clinical programs, A-623 and A-001. A-002 and A-001 inhibit a novel enzyme target known as secretory phospholipase A2, or sPLA2. Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease. A-623 targets elevated levels of B-lymphocyte stimulator, or BLyS (also known as BAFF), which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis, multiple sclerosis, Sjögren’s Syndrome, Graves’ Disease and others. Anthera Pharmaceuticals, Inc. is headquartered in Hayward, California. “
Several other analysts have also commented on the stock. HC Wainwright restated a buy rating and issued a $3.00 price objective on shares of Anthera Pharmaceuticals in a report on Tuesday, September 19th. ValuEngine upgraded shares of Anthera Pharmaceuticals from a strong sell rating to a sell rating in a report on Sunday, December 31st.
Anthera Pharmaceuticals (NASDAQ:ANTH) last issued its quarterly earnings data on Monday, November 6th. The biopharmaceutical company reported ($0.58) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.90) by $0.32. During the same quarter in the previous year, the business earned ($4.85) earnings per share. analysts forecast that Anthera Pharmaceuticals will post -3.09 EPS for the current fiscal year.
A hedge fund recently raised its stake in Anthera Pharmaceuticals stock. Wedbush Securities Inc. lifted its position in shares of Anthera Pharmaceuticals Inc (NASDAQ:ANTH) by 75.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 73,764 shares of the biopharmaceutical company’s stock after acquiring an additional 31,800 shares during the period. Wedbush Securities Inc. owned approximately 0.68% of Anthera Pharmaceuticals worth $106,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 16.10% of the company’s stock.
About Anthera Pharmaceuticals
Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about Anthera Pharmaceuticals? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Anthera Pharmaceuticals and related companies.